New Mexico Clinical Trials Report — April 2026

For New Mexicans considering participation in clinical research, April 2026 presents a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 28 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 5 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on specific types of cancer, neurological conditions, and rare diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Recurrent endometrial carcinoma
• Autism spectrum disorder
• Advanced breast cancer
• Atrial fibrillation
• Autism or autistic traits
• Developmental delay
• Breast cancer
• Avascular necrosis
• Cervical carcinoma
• Chronic granulomatous disease (CGD)

These studies represent diverse areas of medical inquiry, from oncology to developmental disorders, highlighting the broad impact of clinical research in New Mexico. The opportunity to participate in these specific areas is time-sensitive, and potential volunteers are encouraged to act quickly.

A Singular New Opportunity: Addressing PTSD in Albuquerque

This month, New Mexico saw the launch of a single new clinical trial, a notable decrease from the 3 trials that opened in March 2026. While the number is modest, this new study offers a focused opportunity for individuals in the state. The new trial is a drug study specifically targeting Post-Traumatic Stress Disorder (PTSD).

This new research initiative is sponsored by the University of New Mexico and is currently recruiting participants in Albuquerque. As a drug trial, it aims to evaluate the safety and efficacy of a new investigational medication for PTSD, a condition that impacts many individuals. For those living with PTSD, this represents a chance to access potentially innovative treatments and contribute to a better understanding of the disorder.

Looking at the broader trend, the number of new trials opening each month has varied. In late 2025, November saw 2 new trials and December surged to 18. The new year began with 5 trials in January 2026, followed by another 5 in February, and 3 in March. This month's single new trial marks a slower pace of new research opportunities compared to recent months.

New Mexico's Research Landscape: Widespread Access and Volunteer Needs

Despite the limited number of new trials this month, New Mexico continues to offer a robust environment for clinical research. There are currently 382 clinical trials actively recruiting participants across the state. These studies are conducted at 198 research sites spread across 13 different cities, ensuring that opportunities are available beyond just the major metropolitan areas.

The geographic distribution of research sites means that residents in various parts of the state may find trials accessible. While the single new trial this month is located in Albuquerque, the overall research network is more expansive. Cities hosting active research include:

• Albuquerque
• Santa Fe
• Las Cruces
• Rio Rancho
• Farmington
• Roswell
• South Valley
• Clovis
• Hobbs
• Alamogordo
• Carlsbad
• Gallup
• Los Lunas

This broad reach helps ensure that a diverse pool of participants can engage with medical research, contributing to findings that are relevant to the state's population.

Participation Opportunities: Healthy Volunteers and Older Adults

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. As mentioned, 5 trials that are closing soon are actively seeking healthy volunteers. Beyond these time-sensitive opportunities, a total of 34 clinical trials are currently recruiting healthy participants statewide. These studies are crucial for establishing baseline data, understanding disease progression, and testing new interventions in a controlled environment.

Regarding specific demographics, the single new trial opened this month is inclusive of older adults. This is a positive sign, as research involving senior populations is vital for addressing age-related health challenges and ensuring new treatments are safe and effective for this demographic. No new trials this month are specifically for children, or exclusively for male or female participants.

While this month did not see the launch of any large-scale Phase 2 or 3 drug trials from major industry sponsors, the ongoing research efforts by institutions like the University of New Mexico remain a cornerstone of the state's clinical research landscape. These academic-led studies often explore foundational questions and innovative approaches to care.

As we look ahead, the continued recruitment for the existing 382 trials, alongside the anticipation of future research initiatives, will shape the landscape of medical advancement in New Mexico. Potential participants are encouraged to regularly check for updates and consider how their involvement can make a meaningful difference in healthcare for themselves and future generations.